Dr. Schneider joined our board in 2024, bringing more than two decades of experience in the health care industry as a physician, scientist and health care executive. She is the co-founder and Chief Executive Officer of Homeward Health, a company committed to rearchitecting the delivery of health and care for nearly 60 million Americans living in rural communities. Prior to co-founding Homeward Health in 2022, she served as President and Chief Medical Officer of Livongo Health, a biotechnology company serving people with chronic conditions, from 2015 to 2020, where she led the company through the largest consumer digital health Initial Public Offering in history and the industry’s largest merger between Livongo and Teladoc Health. She also served in multiple leadership roles at Castlight Health, a health care navigation company for self-insured companies, from 2010 to 2015, most recently as Chief Medical Officer. Dr. Schneider serves on the board of directors at Jasper Health and Maven Health. She was previously a member of the board of directors at two special purpose acquisition companies (SPACs): Revolution Healthcare Acquisition Corp. (from March 2021 to December 2022) and Health Assurance Acquisition Corp. (from September 2020 until it liquidated in November 2022). She has been honored by Modern Healthcare as one of the “100 Most Influential People in Healthcare” and by Fierce Healthcare as a “Woman of Influence” for her work empowering women and modeling diversity and inclusion in the workplace. Dr. Schneider holds a B.S. in biology from the College of the Holy Cross, an M.D. from Johns Hopkins University School of Medicine, and an M.S. in health services research from Stanford University.

Ms. Thornberry joined our board in 2023. She founded and served as Chief Executive Officer of Kallyope, a clinical stage biotechnology company, from its launch in 2015 until 2021, and remains on Kallyope’s board of directors and is Chair of Research and Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical research in diabetes, obesity and women’s health. Among her many notable scientific accomplishments, Ms. Thornberry initiated and led Merck’s dipeptidyl peptidase 4 (DPP-4) project, which resulted in the discovery and commercialization of JANUVIA® for the treatment of type 2 diabetes. She also identified the first caspase, interleukin-1β converting enzyme (ICE/caspase-1). For her scientific contributions she has received numerous awards, including the Merck Presidential Fellowship, Merck Directors Award, Heroes of Chemistry Award from the American Chemical Society, and in 2011, the Pharmaceuticals Research and Manufacturers of America (PhRMA) Discoverers Award, which honors research scientists whose work has been of special benefit to humankind. In addition to her role at Kallyope, she serves on the board of directors of Schrödinger, Inc., Denali Therapeutics Inc. and the New York Genome Center. She serves as an advisor to GV (Google Ventures) and is a member of NYC’s Mayor’s Life Sciences (LifeSciNYC) Advisory Council. Ms. Thornberry holds a Bachelor of Science degree in chemistry and biology from Muhlenberg College.